Blue Cross Blue Shield of Massachusetts will no longer cover GLP-1 drugs for weight loss as part of its standard benefits, the Boston Globe reported April 17.
In a statement shared with Becker’s, a BCBS Massachusetts spokesperson said the company will continue to cover GLP-1 drugs for diabetes. BCBS Massachusetts will also give large employers the choice of whether to continue coverage of the drugs for weight loss.
“We’re mindful that drugmakers’ prices are putting a big burden on our employer customers, which is why we are offering them the choice to cover or exclude GLP-1 medications for weight loss,” the spokesperson said.
Here are five things to know:
- BCBS Massachusetts reported a $400 million operating loss in 2024. Spending on GLP-1 drugs was the single largest factor behind the loss, the company’s executives said in February.
- Other insurers have made similar decisions. BCBS Michigan stopped covering GLP-1 medications for weight loss in its fully insured, large group commercial plans at the beginning of 2025.
- Around 50,000 BCBS Massachusetts members are taking GLP-1 drugs, with around 80% taking these drugs for weight loss, per the Boston Globe.
- GLP-1 drugs include Ozempic, Wegovy, Monjauro, Zepbound and others. The majority of GLP-1 drugs are approved to treat type 2 diabetes, while Wegovy and Zepbound are approved for weight loss. These drugs can cost upwards of $1,000 a month.
- Research published by the Blue Cross Blue Shield Association in 2024 found nearly 6 in 10 adults prescribed a GLP-1 drug for weight loss discontinued the drug before seeing meaningful clinical benefits.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
